Back to search

Article

Reduced 4E-BP1 activity leads to acquired capivasertib resistance via increased cap-dependent protein synthesis

2025-10-13

Abstract excerpt

<h4>Background</h4> The PI3K/AKT/mTOR (PAM) pathway is frequently dysregulated in human cancers and is a major target of therapeutic intervention, exemplified by the newly approved AKT inhibitor capivasertib. However, clinical responses are often limited by the emergence of acquired drug resistance. <h4>Methods</h4> To uncover potential mechanisms underlying acquired resistance to capivasertib, we developed a dr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
eb8ae8cd-20de-52e8-9d97-56929d5daa47
DOI
10.1101/2025.10.10.681642
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Reduced 4E-BP1 activity leads to acquired capivasertib resistance via increased cap-dependent protein synthesisDOI 10.1101/2025.10.10.681642
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axisSemantic proximity
mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors.Semantic proximity
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.Semantic proximity
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.Semantic proximity
Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian CancerSemantic proximity
Lost in translation: dysregulation of cap-dependent translation and cancer.Semantic proximity
CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.Semantic proximity
mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAsSemantic proximity
Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphomaSemantic proximity
Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K-Mutated Tumor.Semantic proximity
Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.Semantic proximity
A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancerSemantic proximity
Select a neighboring publication to make it the new centre.